|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The KRASG12R mutation displays uneven prevalence among cancers that harbor the highest occurrence of KRAS mutations: it is rare in lung and colorectal cancers (~1%), yet relatively common (~20%) in pancreatic ductal adenocarcinoma (PDAC), suggesting context-specific properties.
|
31649109 |
2020 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
According to cancer-genome sequences, > 90% of cases of pancreatic ductal adenocarcinoma (PDAC) harbor active KRAS mutations.
|
31746520 |
2020 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutations and miRNA dysregulation (e.g. miR-21-5p oncomiR) play key roles in Pancreatic Ductal Adenocarcinoma (PDAC), leading to rapid progression of the disease.
|
31523393 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The UCA1/KRAS axis promotes human pancreatic ductal adenocarcinoma stem cell properties and tumor growth.
|
30949406 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IQ motif containing GTPase-activating protein 1 (IQGAP1) acts as a scaffold for aberrant mitogen-activated protein kinase (MAPK) signaling driven by KRAS mutations in pancreatic ductal adenocarcinoma (PDAC).
|
30540680 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pancreatic ductal adenocarcinoma (PDAC), like many KRAS-driven tumors, preferentially loses CDKN2A that encodes an endogenous CDK4/6 inhibitor to bypass the RB-mediated cell cycle suppression.
|
30696953 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, in pancreatic ductal adenocarcinoma (PDAC) there are only four abundantly common driver mutations (KRAS, CDKN2A, TP53, and SMAD4), which are not currently actionable.
|
31639254 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
KRAS is one of the most frequently mutated proto-oncogenes in pancreatic ductal adenocarcinoma (PDAC) and aberrantly activated in triple-negative breast cancer (TNBC).
|
30654191 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic KRAS mutation plays a key role in pancreatic ductal adenocarcinoma (PDAC) tumorigenesis with nearly 95% of PDAC harboring mutation-activated KRAS, which has been considered an undruggable target.
|
31467540 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the "CKP" mouse pancreatic ductal adenocarcinoma (PDAC) model driven by mutant K-Ras, Ctbp2 haploinsufficiency prolonged survival, abrogated peritoneal metastasis, and caused dramatic downregulation of c-Myc, a known critical dependency for TIC activity and tumor progression in PDAC.
|
31586042 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The highest frequencies of KRAS mutations occur in colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC).
|
31521603 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Most pancreatic ductal adenocarcinoma (PDAC) develops from pancreatic epithelial cells bearing activating mutant KRAS genes through precancerous lesions, i.e. acinar-to-ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN).
|
30705405 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In mice, a high-fat diet (HFD) and expression of oncogenic KRAS lead to development of invasive pancreatic ductal adenocarcinoma (PDAC) by unknown mechanisms.
|
31352001 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Pancreatic ductal adenocarcinoma (PDA) is characterized by an activating mutation in KRAS.
|
30938713 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma.
|
31492820 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the context of pancreatic ductal adenocarcinoma (PDAC), oncogenic KRAS induces benign pancreatic intraepithelial neoplasias (PanINs), which exhibit features of oncogene-induced senescence.
|
30614183 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prediction of Recurrence With KRAS Mutational Burden Using Ultrasensitive Digital Polymerase Chain Reaction of Radial Resection Margin of Resected Pancreatic Ductal Adenocarcinoma.
|
30747828 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Obesity driven by chronic consumption of high-fat diet (HFD) is a major risk factor for oncogenic KRAS-mediated pancreatic ductal adenocarcinoma (PDAC).
|
30819189 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Pancreatic ductal adenocarcinoma (PDAC) is a dominantly (~95%) KRAS-mutant cancer that has extremely poor prognosis, in part this is due to its strong intrinsic resistance towards almost all therapeutic agents.
|
30653981 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Activating <i>KRAS</i> mutations are found in nearly all cases of pancreatic ductal adenocarcinoma (PDAC), yet effective clinical targeting of oncogenic KRAS remains elusive.
|
31263025 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pancreatic ductal adenocarcinoma (PDAC) is characterized by KRAS- and autophagy-dependent tumorigenic growth, but the role of KRAS in supporting autophagy has not been established.
|
30833752 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Concentrations of trace elements and KRAS mutations in pancreatic ductal adenocarcinoma.
|
31066938 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The MED-Amp assay successfully detected KRAS mutant ctDNA in 86% plasma samples obtained from patients with metastatic pancreatic ductal adenocarcinoma.
|
31072097 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on experimental results, we have recently put forward a hypothesis that the coordination of CaM and PI3Kα with K-Ras4B forms a CaM-PI3Kα-K-Ras4B ternary complex, which leads to the formation of pancreatic ductal adenocarcinoma.
|
29300353 |
2018 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
There remains intense interest in tractable approaches to target or silence the KRAS oncoprotein as a rational therapeutic strategy to attack pancreatic ductal adenocarcinoma (PDAC) and other cancers that overexpress it.
|
29321164 |
2018 |